Pharma company Cipla on Saturday informed that the US FDA has classified the company's manufacturing facility in Virgonagar, Bengaluru as a Voluntary Action Indicate (VAI). The company said in an exchange filing that the US FDA conducted a Good Manufacturing Practices inspection at the company's manufacturing unit between November 7-13, 2024.

Voluntary Action Indicate (VAI) status means that objectionable conditions or practices were found at the facility, but the agency (USFDA) is not prepared to take or recommend any administrative or regulatory action. It is lower than Official Action Indicate (OAI) status, which means that regulatory and/or administrative action is recommended.

The company's revenue for the quarter ended December 2024 was ₹ 7,073 crore, an increase of 7 per cent over the previous year. The company's profit has increased by 49 per cent to ₹ 1,570 crore from the year-ago period. Stock performance The company's stock closed 0.10 per cent down at Rs 1,470 on Monday. The company's stock has seen a gain of 3.51 per cent in the last one year.